ES2785094T3 - Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados - Google Patents

Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados Download PDF

Info

Publication number
ES2785094T3
ES2785094T3 ES12850971T ES12850971T ES2785094T3 ES 2785094 T3 ES2785094 T3 ES 2785094T3 ES 12850971 T ES12850971 T ES 12850971T ES 12850971 T ES12850971 T ES 12850971T ES 2785094 T3 ES2785094 T3 ES 2785094T3
Authority
ES
Spain
Prior art keywords
glutamine
salt
diabetes
use according
person
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12850971T
Other languages
English (en)
Spanish (es)
Inventor
Yutaka Niihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emmaus Medical Inc
Original Assignee
Emmaus Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48470183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2785094(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emmaus Medical Inc filed Critical Emmaus Medical Inc
Application granted granted Critical
Publication of ES2785094T3 publication Critical patent/ES2785094T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ES12850971T 2011-11-21 2012-11-17 Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados Active ES2785094T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161629633P 2011-11-21 2011-11-21
PCT/US2012/000557 WO2013077893A1 (en) 2011-11-21 2012-11-17 Methods and compositions for the treatment of diabetes and related symptoms

Publications (1)

Publication Number Publication Date
ES2785094T3 true ES2785094T3 (es) 2020-10-05

Family

ID=48470183

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12850971T Active ES2785094T3 (es) 2011-11-21 2012-11-17 Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados

Country Status (10)

Country Link
US (2) US20130143968A1 (enExample)
EP (2) EP3437649A1 (enExample)
JP (4) JP6089042B2 (enExample)
CN (3) CN108354916A (enExample)
BR (1) BR112014011898A2 (enExample)
ES (1) ES2785094T3 (enExample)
HK (1) HK1257401A1 (enExample)
IN (1) IN2014KN01037A (enExample)
PH (2) PH12020550726B1 (enExample)
WO (1) WO2013077893A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
JP2021527670A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 筋肉中の脂肪浸潤の治療のための組成物及び方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
CA2418543A1 (en) * 2001-06-27 2003-01-09 Probiodrug Ag New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
SE0201713D0 (sv) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
TWI351278B (en) * 2002-03-01 2011-11-01 Nisshin Pharma Inc Agent for preventing and treating of liver disease
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
CA2774197A1 (en) * 2006-04-22 2008-04-03 Harbor Biosciences, Inc. Drugs and uses to modulate inflammation, metabolic disorders and other conditions
WO2008038771A1 (en) * 2006-09-29 2008-04-03 Ajinomoto Co., Inc. Glutamine-containing composition for increasing blood flow
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
EP2057905A1 (en) * 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
WO2010081079A2 (en) * 2009-01-12 2010-07-15 Biokier Inc. Composition and method for treatment of diabetes
NL1036746C2 (nl) * 2009-03-20 2010-09-21 Glnp Holding B.V. Kit van onderdelen bevattende l-glutamine en egcg.
JP2013505936A (ja) * 2009-09-23 2013-02-21 バイオキアー・インコーポレイテッド 糖尿病の治療のための組成物および方法

Also Published As

Publication number Publication date
PH12014501052A1 (en) 2014-06-30
JP6550160B2 (ja) 2019-07-24
HK1257401A1 (zh) 2019-10-18
PH12020550726B1 (en) 2022-11-09
EP2782588A1 (en) 2014-10-01
CN108478551A (zh) 2018-09-04
EP2782588B1 (en) 2020-04-15
BR112014011898A2 (pt) 2017-05-16
WO2013077893A1 (en) 2013-05-30
EP2782588A4 (en) 2015-05-20
PH12020550726A1 (en) 2021-06-14
PH12014501052B1 (en) 2020-10-09
US20190192463A1 (en) 2019-06-27
EP3437649A1 (en) 2019-02-06
CN103945858A (zh) 2014-07-23
JP2018115175A (ja) 2018-07-26
IN2014KN01037A (en) 2015-10-09
JP2014533689A (ja) 2014-12-15
CN108354916A (zh) 2018-08-03
JP6089042B2 (ja) 2017-03-01
US20130143968A1 (en) 2013-06-06
JP2017052766A (ja) 2017-03-16
JP6389495B2 (ja) 2018-09-12
JP2018199692A (ja) 2018-12-20

Similar Documents

Publication Publication Date Title
US11141399B2 (en) Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
ES2959111T3 (es) Composiciones farmaceuticas que comprenden glitazonas y activadores de Nrf2
ES2820025T3 (es) Uso de derivados 2-hidroxilados de ácidos grasos poliinsaturados como medicamentos
US11224585B2 (en) Compositions containing omega-3 oil and uses thereof
ES2948609T3 (es) Prevención y tratamiento de migraña
CN103285394B (zh) 使用硝化脂质治疗脂质病症和肥胖以及与脂质和肥胖相关的病状
US20180085334A1 (en) Methods of treating pediatric metabolic syndrome
EP1915144A2 (en) Method to reduce oxidative damage and improve mitochondrial efficiency
ES2785094T3 (es) Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados
JP2017519028A (ja) 重度の高トリグリセリド血症の処置
WO2021150958A1 (en) Treatment methods using a combination of pantethine and a vanin agonist
ES2676529T3 (es) Composición útil para el tratamiento de la diabetes tipo 2
CN110139645A (zh) 用于预防和/或治疗恶病质的ω-3脂肪酸组合物
CN121176626A (zh) 用于调控神经递质的膳食补充剂及其制备方法和应用
WO2023100938A1 (ja) 酸化ストレス緩和方法
CN117653642A (zh) 格列本脲促进nad+水平的用途
HK1216847A1 (zh) 用於产生升高和持久的酮症的组合物和方法